Skip to main content

Search Trends Ads Appearances Podcasts API

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.

OncoPharm

Endurance Part 2

Jul 16, 2026 · 15 min · 13 segments

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion…

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Learning Oncology Companion…

Speakers: John BazarHost

Top entities: Food and Drug Administration×6 Pembrolizumab×2 Eastern Cooperative Oncology Group×2 The New England Journal of Medicine×4 Enfortumab vedotin

Spotify Apple Podcasts YouTube Amazon Music Website

Show signals: SuitabilitySafeBiasNot politicalAudience≈1k followers

FDA Update – Isatuximab Sub-Q Approval0:23 – 0:55

0:23

We're going to talk mostly about lenalidomide maintenance in multiple myeloma, but first a couple tips.

0:31

FDA approval updates from last week.

0:34

There is now an isatuximab subcutaneous formulation that has been, has approved isatuximab.

0:44

It was late to the party.

0:46

It came after daratumab.

0:48

No, you know, kind of a me too drug.

0:51

But there is now a subcutaneous form.

0:53

that is worth, you know, people knowing about.

Food and Drug AdministrationGovernment OrganizationFederal agency
96%6 mentions
PembrolizumabEntityDrug
89%2 mentions
Eastern Cooperative Oncology GroupOrganization
82%2 mentions
The New England Journal of MedicinePeriodicalJournal
75%4 mentions
Enfortumab vedotinEntityDrug
68%1 mention
Kaplan–Meier estimatorEntity
61%1 mention
ToxicityEntity
54%1 mention
Risk Evaluation and Mitigation StrategiesEntity
46%2 mentions
multiple myelomaEntityInfection
39%1 mention
East Tennessee State UniversityCollege or UniversityPublic university in Johnson City, Tennessee
32%1 mention
BortezomibEntityMedication
25%1 mention
LenalidomideEntityMedication
18%1 mention
ChristmasEntityFestival
11%1 mention
SWOGOrganization
4%1 mention

HealthcareHealth
OncologyHealth > Healthcare
Multiple MyelomaHealth > Healthcare > Oncology
Treatment ProtocolsHealth > Healthcare > Patient Care
FDA ApprovalsHealth > Healthcare > Clinical Trials
Bladder CancerHealth > Healthcare > Oncology
Drug TherapiesHealth > Healthcare
Survival RatesHealth > Healthcare > Patient Care > Treatment Protocols
Cancer TreatmentsHealth > Healthcare > Clinical Trials > FDA Approvals
Patient CareHealth > Healthcare
Clinical TrialsHealth > Healthcare
Health
Lenalidomide MaintenanceHealth > Healthcare > Oncology > Multiple Myeloma
Infortimab VedotinHealth > Healthcare > Oncology > Bladder Cancer
ChemotherapyHealth > Healthcare > Drug Therapies
Cisplatin-Based TreatmentsHealth > Healthcare > Drug Therapies > Chemotherapy

FDA Update – Isatuximab Sub-Q Approval0:23 – 0:55

0:23

We're going to talk mostly about lenalidomide maintenance in multiple myeloma, but first a couple tips.

0:31

FDA approval updates from last week.

0:34

There is now an isatuximab subcutaneous formulation that has been, has approved isatuximab.

0:44

It was late to the party.

0:46

It came after daratumab.

0:48

No, you know, kind of a me too drug.

0:51

But there is now a subcutaneous form.

0:53

that is worth, you know, people knowing about.

Sign up to see more

The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode

Create an account Already have an account? Log in

No account is needed to search Radar.